


Edoceo Devices - Viral and Bacterial Detection Revenue
Biotechnology Research • Boulder, Colorado, United States • 1-10 Employees
Edoceo Devices - Viral and Bacterial Detection revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Key Contact at Edoceo Devices - Viral and Bacterial Detection
Larry Doan
Director
Company overview
| Headquarters | 1712 Pearl St, Boulder, Colorado 80302, US |
| Website | |
| NAICS | 541714 |
| Keywords | Med-Technology And Biotechnology |
| Employees | 1-10 |
| Socials |
About Edoceo Devices - Viral and Bacterial Detection
Edoceo Devices is an emerging med-tech & biotech American company with Exclusive and Groundbreaking Biosensor Technology that could Help in the fight against COVID-19 – as well as Future Viral and Bacterial Threats to our normal family way of life. The priority is finalizing the development and marketing of this technology to produce two on-site proprietary detection biosensors - with the goal of providing essential rapid early warning to the presence of harmful pathogens: • Edoceo B-DetectTM - A portable virulent bacterial Testing device • Edoceo V-DetectTM - A portable virus biosensing device Edoceo B-Detect and V-Detect have the potential to change the world of rapid, portable, affordable, and accurate testing for pathogens including virulent bacteria and the presence of a range of viruses. These innovative detection platforms are being developed for the aquaculture, veterinary, health care, food processing and home monitoring markets, amongst others – Edoceo detection devices are based on the work of their Chief Science Officer, the Multi-Award-Winning Dr. Kenneth Reardon, in collaboration with many years of study and research by the scientists at Colorado State University that is exclusively licensed to Edoceo. *Breaking News* As a potential bonus to investors, and having secured substantial access to supplies, Edoceo Devices are commencing commercialization of a rapid (< 17 minutes), simple, saliva-based antigen test for the Coronavirus – Edoceo A-Detect which is already CE marked for distribution in the European Union and we are also planning a US FDA Emergency Use Application for distribution and sales in the United States.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Edoceo Devices - Viral and Bacterial Detection has never raised funding before.
Edoceo Devices - Viral and Bacterial Detection Tech Stack
Discover the technologies and tools that power Edoceo Devices - Viral and Bacterial Detection's digital infrastructure, from frameworks to analytics platforms.
Web servers
Form builders
JavaScript libraries
Tag managers
Miscellaneous
Analytics
Page builders
JavaScript libraries
Cookie compliance
Analytics
Video players
Frequently asked questions
4.8
40,000 users



